Search research articles
Contact Us
Filters
Showing results (171-180 of 186) with videos related to
Page
of 19
Sort By:
British Journal of Cancer
|
September 17, 2014
The AURORA initiative for metastatic breast cancer
D Zardavas, M Maetens, A Irrthum, et al.
Anti-Cancer Drugs
|
March 23, 2001
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study
F Duffaud, M E van der Burg, M Namer, et al.
The Pharmacogenomics Journal
|
August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
C F Spraggs, L R Parham, L P Briley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 17, 2013
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)
R A Popescu, R Schäfer, R Califano, et al.
ESMO Open
|
April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
B Gyawali, E G E de Vries, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 3, 2012
Genomic grade adds prognostic value in invasive lobular carcinoma
O Metzger-Filho, S Michiels, F Bertucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2025
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
N I Cherny, S F Oosting, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2023
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
B Kiesewetter, U Dafni, E G E de Vries, et al.
Genomics Data
|
October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients
B Haibe-Kains, C Desmedt, A Di Leo, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 186) with videos related to
Sort By:
Page
of 19
British Journal of Cancer
|
September 17, 2014
The AURORA initiative for metastatic breast cancer
D Zardavas, M Maetens, A Irrthum, et al.
Anti-Cancer Drugs
|
March 23, 2001
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study
F Duffaud, M E van der Burg, M Namer, et al.
The Pharmacogenomics Journal
|
August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
C F Spraggs, L R Parham, L P Briley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 17, 2013
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)
R A Popescu, R Schäfer, R Califano, et al.
ESMO Open
|
April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
B Gyawali, E G E de Vries, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 3, 2012
Genomic grade adds prognostic value in invasive lobular carcinoma
O Metzger-Filho, S Michiels, F Bertucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2025
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
N I Cherny, S F Oosting, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2023
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
B Kiesewetter, U Dafni, E G E de Vries, et al.
Genomics Data
|
October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients
B Haibe-Kains, C Desmedt, A Di Leo, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Page
of 19